Abstract

Azstarys in Ora-Blend Single Dose

Author(s): Allen Loyd V Jr

Issue: May/Jun 2022 - Volume 26, Number 3

Page(s): 233

Download in electronic PDF format for $75
  • Azstarys in Ora-Blend Single Dose Page 1

Note: Electronic version includes supplemental material.

Abstract

A formulation for preparing Azstarys in Ora-Blend Single Dose. Includes ingredients, method of preparation, discussion, and references for the compounding pharmacist.

Related Keywords

  • formulation
  • Azstarys
  • central nervous system stimulant
  • attention-deficit hyperactivity disorder
  • ADHD
  • children
  • single dose preparation
  • dexmethylphenidate prodrug
  • serdexmethylphenidate

Related Categories

  • FORMULATIONS
  • MENTAL HEALTH
  • PEDIATRICS
  • DOSAGE FORMS/DRUG CARRIERS
  • NEUROLOGY

Printer-Friendly Version

Related Articles from IJPC

Issue/Page
View/Buy		 Title/Author
(Click for Abstract / Details / Purchase)
May/Jun 2022
Pg. 233
Azstarys in Ora-Blend Single Dose
Author(s): Allen Loyd V Jr
Mar/Apr 1997
Pg. 87-89
Attention Deficit Hyperactivity Disorder
Author(s): Allen Loyd V Jr
Jan/Feb 2001
Pg. 21-22
Methylphenidate in the Treatment of Attention Deficit Disorders
Author(s): Tenreiro Kim
Nov/Dec 2014
Pg. 496
Dexmethylphenidate Hydrochloride 2.5-mg, 5-mg, or 10-mg Capsules
Author(s): Allen Loyd V Jr
Nov/Dec 2003
Pg. 441-447
Single-Patient Trials, Extemporaneously Compounded Products and Pharmaceutical Care
Author(s): Fassett William E
Jan/Feb 2001
Pg. 6-8
Pediatric Compounding: Coloring Outside the Lines
Author(s): Preckshot John
Nov/Dec 2023
Pg. 468-473
Case Study: Personalized Oral Low-dose Naltrexone Titration for Pain Management
Author(s): Rodriguez Franklin, Carvalho Maria, Banov Fabiana
Sep/Oct 2021
Pg. 414
Clonidine 0.01-mg/mL in Ora-Blend Suspension
Author(s): Allen Loyd V Jr
Mar/Apr 2010
Pg. 171-173
Low Dose Naltrexone: Side Effects and Efficacy in Gastrointestinal Disorders
Author(s): Ploesser Jennifer, Weinstock Leonard B, Thomas Erin
Nov/Dec 2014
Pg. 501
Methylphenidate Hydrochloride 10-mg Capsules
Author(s): Allen Loyd V Jr
May/Jun 2016
Pg. 239-246
Topical Metered-dosing Dispenser Performance Evaluation
Author(s): Liu Qiang, Kupiec Thomas C, Vu Nicole T
Jan/Feb 2018
Pg. 41-46
Sterile Basics of Compounding: Relationship Between Syringe Size and Dosing Accuracy
Author(s): Kosinski Tracy M, Brown Michael C, Zavala Pedro J
Jul/Aug 2018
Pg. 270-278
Compounded Low-dose Naltrexone for the Treatment of Guttate Psoriasis: A Case Report
Author(s): Muller George, Grieshaber Robert, Talley J Floyd, Riepl Mike, Fellows Don
Nov/Dec 2021
Pg. 506
Quetiapine Fumarate 10 mg/mL in Ora-Blend
Author(s): Allen Loyd V Jr
Jul/Aug 2018
Pg. 268
PreScription: Factors Related to Drug Waste and Pharmacy Solutions
Author(s): Allen Loyd V Jr
Nov/Dec 2018
Pg. 496
Hydroxyurea 100 mg/mL in Ora-Plus:Ora-Sweet, Ora-Plus: Ora-Sweet SF, Ora-Blend or Oral-Blend SF Oral Suspensions
Author(s): Allen Loyd V Jr
Jan/Feb 2010
Pg. 32-38
Unit Dose Packaging and Repackaging of Solid and Liquid Dosage Forms in an Institutional Setting
Author(s): McElhiney Linda F
Sep/Oct 2018
Pg. 358-366
Current Trends and Emerging Priorities in Compounded Preparations for Children
Author(s): Parrish Richard H II
Mar/Apr 2020
Pg. 94-96
Low-dose Naltrexone Therapy for Psoriasis
Author(s): Weinstock Leonard B, Cottel Jill, Aldridge Lindsey, Egeberg Alexander
Jul/Aug 2020
Pg. 346-351
Single Center Experience with Robot Technologies for Sterile Compounding: A Retrospective Review
Author(s): Milibari Loay, Cotugno Michael, Belisle Caryn, Rocchio Megan, Patterson Robert F, Chacon Pablo, Fanikos John, Vo Peter